[PDF][PDF] Preclinical studies of [Cu] ATSM as a PET radiopharmaceutical for fibrosarcoma imaging

A Jalilian, N Rostampour, P Rowshanfarzad… - Acta …, 2009 - sciendo.com
A Jalilian, N Rostampour, P Rowshanfarzad, K Shafaii, M Kamali-Dehghan, M Akhlaghi
Acta Pharmaceutica, 2009sciendo.com
ATSM) was prepared using in house-made diacetyl-bis (N4--methylthiosemicarbazone)(
ATSM) ligand and [61Cu] CuCl2 produced via the natZn (p, x) 61Cu (180 mA proton
irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method.[61Cu] ATSM
radiochemical purity was> 98%, as shown by HPLC and RTLC methods.[61Cu] ATSM was
administered into normal and tumor bearing rodents for up to 210 minutes, followed by
biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation …
ATSM) was prepared using in house-made diacetyl-bis (N4--methylthiosemicarbazone)(ATSM) ligand and [61Cu] CuCl2 produced via the natZn (p, x) 61Cu (180 mA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method.[61Cu] ATSM radiochemical purity was> 98%, as shown by HPLC and RTLC methods.[61Cu] ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging.[61Cu] ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.
sciendo.com
以上显示的是最相近的搜索结果。 查看全部搜索结果